series-c-plus
Stage
1
Investors
About
Stoke Therapeutics is a clinical-stage biotechnology company developing genetic medicines that upregulate protein production by modulating RNA splicing using antisense oligonucleotides (its TANGO platform) to treat rare genetic diseases.
Explore Stoke Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.